APTO Stock Price, Aptose Biosciences Inc Quote, Chart

Market Summary

USD1.18-0.01

Delayed

-0.84%

APTO Stock Price

View Fullscreen

APTO RSI Chart

APTO Valuation

Market Cap

19.2M

Price/Earnings (Trailing)

-0.41

Price/Free Cashflow

-0.43

APTO Price/Sales (Trailing)

APTO Profitability

Return on Equity

-47.2K%

Return on Assets

-368.64%

Free Cashflow Yield

-235.09%

APTO Fundamentals

APTO Earnings

Earnings (TTM)

-47.2M

Earnings Growth (Yr)

29.51%

Earnings Growth (Qtr)

19.36%

Breaking Down APTO Revenue

Last 7 days

-4.1%

Last 30 days

-6.3%

Last 90 days

-39.5%

Trailing 12 Months

-83.7%

How does APTO drawdown profile look like?

APTO Financial Health

Current Ratio

0.97

APTO Investor Care

Shares Dilution (1Y)

160.30%

Diluted EPS (TTM)

-6.33

Tracking the Latest Insider Buys and Sells of Aptose Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 22, 2023	seizinger bernd r.	bought	53,380	3.14	17,000	-
Jan 19, 2023	ledru philippe	acquired	-	-	100,000	chief commercial officer
Jan 19, 2023	bejar rafael	acquired	-	-	100,000	sr. vp, chief medical officer
Jan 19, 2023	rice william g.	acquired	-	-	150,000	chair, president & ceo
Jan 19, 2023	payne fletcher	acquired	-	-	100,000	sr vp & chief fin. officer
Sep 19, 2022	rice william g.	bought	6,834	0.6834	10,000	chair, president & ceo
Sep 19, 2022	payne fletcher	bought	6,775	0.6775	10,000	sr vp & chief fin. officer
Jun 06, 2022	rice william g.	bought	9,681	0.9681	10,000	chair, president & ceo
Dec 20, 2021	burger denis r	bought	14,490	1.449	10,000	-
Dec 16, 2021	platzer erich	bought	137,900	1.379	100,000	-

Which funds bought or sold APTO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	reduced	-62.11	-170,969	56,262	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-58.48	-112,659	42,647	-%
May 15, 2024	Royal Bank of Canada	reduced	-79.77	-14,000	3,000	-%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	reduced	-58.31	-589	221	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-39,340	-	-%
May 15, 2024	Nantahala Capital Management, LLC	reduced	-63.15	-463,294	146,976	0.01%
May 15, 2024	Cetera Advisors LLC	reduced	-12.47	-25,741	35,390	-%
May 15, 2024	PACIFIC CAPITAL WEALTH ADVISORS, INC	unchanged	-	-5.00	10.00	-%
May 15, 2024	Annandale Capital, LLC	reduced	-64.29	-144,000	44,000	0.01%
May 15, 2024	Beaird Harris Wealth Management, LLC	unchanged	-	-220	415	-%

Are Funds Buying or Selling APTO?

Are funds buying APTO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own APTO

No. of Funds

Unveiling Aptose Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 26, 2024	hanmi pharmaceutical co., ltd.	19.02%	2,989,415	SC 13D/A
Feb 14, 2024	nantahala capital management, llc	1.5%	120,132	SC 13G/A
Feb 05, 2024	hanmi pharmaceutical co., ltd.	22.17%	2,989,415	SC 13D/A
Sep 12, 2023	hanmi pharmaceutical co., ltd.	12.07%	884,152	SC 13D
Feb 14, 2023	nantahala capital management, llc	6.6%	6,052,867	SC 13G/A
Jan 17, 2023	fletcher aaron g.l.	3.6%	3,311,458	SC 13G
Feb 14, 2022	nantahala capital management, llc	8.5%	7,604,693	SC 13G/A
Feb 11, 2022	orbimed capital llc	0.00%	0	SC 13G/A
Aug 10, 2021	wilson donald r. jr.	993%	8,888,275	SC 13G/A
Feb 17, 2021	consonance capital management lp	-	0	SC 13G/A

Recent SEC filings of Aptose Biosciences Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	DEF 14A	DEF 14A
May 14, 2024	8-K	Current Report
May 14, 2024	10-Q	Quarterly Report
May 10, 2024	4	Insider Trading
May 06, 2024	8-K	Current Report
May 01, 2024	8-K	Current Report
Apr 30, 2024	PRE 14A	PRE 14A
Apr 29, 2024	10-K/A	Annual Report
Apr 26, 2024	SC 13D/A	13D - Major Acquisition
Apr 26, 2024	8-K	Current Report

Peers (Alternatives to Aptose Biosciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Aptose Biosciences Inc News

Latest updates

Aptose Biosciences Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-1.5%	13.00	13.00	21.00	27.00	39.00	51.00	57.00	65.00	73.00	83.00	97.00	106	115	126	135	85.00	93.00	100	32.00	38.00	20.00
Current Assets	-0.6%	12.00	12.00	20.00	25.00	38.00	50.00	57.00	64.00	72.00	82.00	96.00	105	114	125	134	84.00	91.00	99.00	31.00	36.00	18.00
Cash Equivalents	-20.6%	7.00	9.00	16.00	8.00	23.00	37.00	28.00	40.00	37.00	39.00	75.00	83.00	87.00	117	100	54.00	60.00	80.00	21.00	27.00	17.00
Net PPE	-17.8%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-20.3%	13.00	16.00	13.00	13.00	13.00	13.00	10.00	9.00	7.00	8.00	9.00	8.00	6.00	7.00	6.00	6.00	5.00	7.00	5.00	4.00	4.00
Current Liabilities	-20.5%	12.00	15.00	12.00	12.00	12.00	12.00	10.00	9.00	7.00	8.00	8.00	8.00	5.00	7.00	5.00	5.00	4.00	6.00	4.00	3.00	3.00
Shareholder's Equity	103.4%	0.00	-2.90	8.00	14.00	26.00	38.00	47.00	55.00	65.00	74.00	89.00	98.00	109	119	129	79.00	87.00	94.00	27.00	34.00	15.00
Retained Earnings	-1.9%	-525	-515	-503	-492	-478	-464	-454	-444	-433	-422	-398	-386	-373	-357	-342	-329	-313	-301	-294	-287	-281
Additional Paid-In Capital	9.7%	79.00	72.00	72.00	71.00	70.00	69.00	68.00	67.00	66.00	64.00	61.00	60.00	57.00	51.00	46.00	46.00	39.00	35.00	35.00	34.00	34.00
Shares Outstanding	97.9%	16.00	8.00	8.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	-	-	-	-	-	-	-
Float	-	-	-	-	30.00	-	-	-	68.00	-	-	-	293	-	-	-	478	-	-	-	143	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-27.1%	-11,763	-9,254	-10,536	-13,503	-11,302	-8,651	-6,979	-7,047	-9,645	-16,044	-8,059	-8,825	-10,376	-10,348	-8,270	-7,164	-8,111	-6,231	-5,184	-5,269	-4,874
Share Based Compensation	96.8%	809	411	599	769	1,874	861	1,053	779	2,514	2,314	1,828	2,164	6,643	4,431	4,905	7,701	4,401	562	504	568	662
Cashflow From Investing	-203.0%	-1,991	1,933	12,953	-1,960	-2,960	17,573	-5,078	10,066	7,505	-20,010	-185	4,999	-20,012	27,967	-4,398	1,479	-12,427	-8,278	-1,042	-8,026	-24.00
Cashflow From Financing	1287.2%	11,847	854	4,902	1,104	50.00	51.00	21.00	29.00	15.00	66.00	-	85.00	75.00	42.00	58,283	46.00	436	73,640	17.00	23,613	6,178

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

APTO Income Statement

2024-03-31

Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue	$ 0	$ 0
Expenses:
Research and development	6,445	8,811
General and administrative	3,315	5,285
Operating expenses	9,760	14,096
Other income/(expense):
Interest income	121	422
Foreign exchange loss	(1)	(2)
Total other income	120	420
Net loss	(9,640)	(13,676)
Other comprehensive loss:
Unrealized (loss) gain on available-for-sale securities	(1)	4
Total comprehensive loss	$ (9,641)	$ (13,672)
Basic loss per common share (in dollars per share)	$ (0.73)	$ (2.22)
Diluted loss per common share (in dollars per share)	$ (0.73)	$ (2.22)
Weighted average number of common shares outstanding (in thousands) used in the calculation of basic loss per common share (in shares)	13,133	6,171
Weighted average number of common shares outstanding used in the calculation of diluted loss per common share ( in shares)	13,133	6,171

APTO Balance Sheet

2024-03-31

Condensed Consolidated Interim Statements of Financial Position (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 7,346	$ 9,252
Investments	1,982
Prepaid expenses	1,819	2,042
Other current assets	674	600
Total current assets	11,821	11,894
Non-current assets:
Property and equipment	125	152
Right-of-use assets, operating leases	850	943
Total non-current assets	975	1,095
Total assets	12,796	12,989
Current liabilities:
Accounts payable to related parties		2,554
Accounts payable	2,421	3,492
Accrued liabilities	9,319	8,829
Current portion of lease liability, operating leases	399	394
Total current liabilities	12,139	15,269
Non-current liabilities:
Lease liability, operating leases	520	621
Total liabilities	12,659	15,890
Shareholders' equity:
Common shares, no par value, unlimited authorized shares, 15,717,701 and 7,942,363 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	450,485	444,806
Additional paid-in capital	79,146	72,146
Accumulated other comprehensive loss	(4,317)	(4,316)
Deficit	(525,177)	(515,537)
Total shareholders’ equity	137	(2,901)
Total liabilities and shareholders’ equity	$ 12,796	$ 12,989

About Aptose Biosciences Inc

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, an orally administered, and potent dual lymphoid and myeloid kinome inhibitor that is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS. It has agreements with CrystalGenomics, Inc. and Hanmi Pharmaceutical Co. Ltd. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

CEO	Dr. William G. Rice Ph.D.
WEBSITE	aptose.com
INDUSTRY	Biotechnology
EMPLOYEES	35

Aptose Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Aptose Biosciences Inc? What does APTO stand for in stocks?

APTO is the stock ticker symbol of Aptose Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aptose Biosciences Inc (APTO)?

As of Fri May 17 2024, market cap of Aptose Biosciences Inc is 19.18 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of APTO stock?

You can check APTO's fair value in chart for subscribers.

What is the fair value of APTO stock?

You can check APTO's fair value in chart for subscribers. The fair value of Aptose Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aptose Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for APTO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aptose Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether APTO is over valued or under valued. Whether Aptose Biosciences Inc is cheap or expensive depends on the assumptions which impact Aptose Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for APTO.

What is 5 year return on Aptose Biosciences Inc's stock?

In the past 10 years, Aptose Biosciences Inc has provided -0.352 (multiply by 100 for percentage) rate of return.